Search Results - Jennifer Tobin

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    A Framework for Convergence Research in the Hazards and Disaster Field: The Natural Hazards Engineering Research Infrastructure CONVERGE Facility by Lori Peek, Jennifer Tobin, Rachel M. Adams, Haorui Wu, Mason Clay Mathews

    Published in Frontiers in Built Environment (2020-07-01)
    Get full text
    Article


  2. 2

    Successful treatment of disseminated Rosai-Dorfman disease with siltuximab by Hannah Lee, Gentry King, Kavita Garg, Zenggang Pan, Jennifer Tobin, William A. Robinson

    Published in Haematologica (2018-07-01)
    Get full text
    Article


  3. 3

    P540: RESULTS FROM A PHASE 1 CLINICAL STUDY OF THE ALL-ORAL REGIMEN OF CC-486 AND VENETOCLAX FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML) by Maria Amaya, Christine Mcmahon, Jonathan Aaron Gutman, Marc Schwartz, Brett Sevens, Connor Sohalski, Jennifer Tobin, Clayton Smith, Craig T Jordan, Daniel Aaron Pollyea

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  4. 4

    Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib by Zohra Nooruddin, Nicholas Miltgen, Qi Wei, Jeffrey Schowinsky, Zengang Pan, Jennifer Tobin, Enkhtsetseg Purev, Jonathan A. Gutman, William Robinson, Daniel A. Pollyea

    Published in Haematologica (2017-05-01)
    Get full text
    Article


  5. 5

    Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia by Amanda C. Winters, Jonathan A. Gutman, Enkhtsetseg Purev, Molly Nakic, Jennifer Tobin, Stephanie Chase, Jeff Kaiser, Lindsey Lyle, Chelsey Boggs, Keri Halsema, Jeffrey T. Schowinsky, Julie Rosser, Mark D. Ewalt, Bradford Siegele, Vishal Rana, Steven Schuster, Diana Abbott, Brett M. Stevens, Craig T. Jordan, Clayton Smith, Daniel A. Pollyea

    Published in Blood Advances (2019-10-01)
    Get full text
    Article


  6. 6

    Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia by Jonathan A. Gutman, Amanda Winters, Andrew Kent, Maria Amaya, Christine McMahon, Clayton Smith, Craig T. Jordan, Brett Stevens, Mohammad Minhajuddin, Shanshan Pei, Jeffrey Schowinsky, Jennifer Tobin, Kelly O’Brien, Angela Falco, Elizabeth Taylor, Constance Brecl, Katie Zhou, Phuong Ho, Connor Sohalski, Jessica Dell-Martin, Olivia Ondracek, Diana Abbott, Daniel A. Pollyea

    Published in Haematologica (2023-04-01)
    Get full text
    Article


Search Tools: